Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0W9PG
|
|||
| Former ID |
DIB016590
|
|||
| Drug Name |
Pyrazinoylguanidine
|
|||
| Synonyms |
PZG
Click to Show/Hide
|
|||
| Indication | Diabetic complication [ICD-11: 5A2Y; ICD-9: 253.5, 588.1] | Discontinued in Phase 2 | [1] | |
| Company |
Sparta Pharmaceuticals Inc
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C6H7N5O
|
|||
| Canonical SMILES |
C1=CN=C(C=N1)C(=O)N=C(N)N
|
|||
| InChI |
1S/C6H7N5O/c7-6(8)11-5(12)4-3-9-1-2-10-4/h1-3H,(H4,7,8,11,12)
|
|||
| InChIKey |
WNBSDCKJFDZMHT-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 60398-24-5
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Sodium channel unspecific (NaC) | Target Info | Modulator | [2] |
| KEGG Pathway | Dopaminergic synapse | |||
| Reactome | Interaction between L1 and Ankyrins | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002279) | |||
| REF 2 | Design, synthesis, and structure-activity relationships of novel 2-substituted pyrazinoylguanidine epithelial sodium channel blockers: drugs for cystic fibrosis and chronic bronchitis. J Med Chem. 2006 Jul 13;49(14):4098-115. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.